Peptides for sleep

A synergistic growth hormone releasing combination for body composition, sleep, and recovery.

• Increased lean muscle mass
• Reduced body fat
• Deeper, more restorative sleep

Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.

• Increased lean body mass
• Deeper sleep and improved REM
• Improved fat metabolism, especially visceral

Synthetic GHRH analog (modified GHRH 1-44) FDA-approved as Egrifta for HIV-associated lipodystrophy. Selectively reduces visceral adipose tissue and modestly elevates IGF-1 with a favorable safety profile relative to exogenous HGH.

• Visceral adipose tissue reduction
• Improved triglyceride and lipid profile
• Modest IGF-1 elevation

Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).

• Increased lean body mass
• Visceral and subcutaneous fat loss
• Faster recovery from training and injury

Skytrofa is a once-weekly, long-acting growth hormone for children with growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug that slowly releases somatropin (hGH) over 7 days, providing stable GH levels with a single weekly injection instead of daily shots.

• Linear growth acceleration in GH-deficient children
• Once-weekly convenience vs. daily injections
• Stable, sustained GH/IGF-1 levels throughout the week

An orally bioavailable, non-peptide ghrelin receptor agonist that produces sustained increases in GH and IGF-1 with once-daily dosing. Taken as a capsule — no reconstitution needed. Studied for sarcopenia, GH deficiency, and recovery support.

• Sustained 24-hour GH and IGF-1 elevation
• Increased fat-free mass over 12 months
• Improved stage IV and REM sleep quality

A research-grade non-peptide ghrelin receptor (GHS-R1a) agonist developed as a successor to MK-677. Vendor and analog modeling describe higher receptor affinity and longer half-life, but human clinical data are not yet published.

• Reportedly higher GHS-R1a affinity than MK-677
• Longer half-life vs. MK-677 (analog modeling)
• Orally bioavailable like MK-677

A synthetic tripeptide (Glu-Asp-Arg) from Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation. Animal studies report reduced ROS in cerebellar granule and PC12 cells, plus improved cognitive outcomes in prenatal hyperhomocysteinemia and Alzheimer's mouse models.

• Reduces ROS in neuronal cells (preclinical)
• Neuroprotective in oxidative-stress models
• Improved offspring cognition in prenatal stress models